日本局部晚期胰臟癌市場－2025-2033年

2024 年日本局部晚期胰臟癌市場規模達到 4,709 萬美元，預計到 2033 年將達到 8,904 萬美元，在 2025-2033 年預測期內的複合年成長率為 7.4%。

市面上局部晚期的胰臟癌（LAPC）是指疾病的一個階段，腫瘤仍然局限於胰臟和周圍區域結構，但尚未轉移到遠端器官，如肝臟、肺臟或遠端淋巴結。在此階段，癌症已局部擴散，並可能影響附近的關鍵結構，包括腸系膜上動脈或門靜脈等血管，以及十二指腸、膽管和脾臟等器官。

在日本，LAPC 通常被歸類為不可切除的，這意味著由於腫瘤包裹或靠近重要血管和神經，因此無法進行手術切除。在這些情況下嘗試手術可能會導致嚴重的併發症，因此非手術治療方式成為主要的治療標準。

日本目前的治療方案強調多模式方法，結合化療（特別是 FOLFIRINOX 或吉西他濱加白蛋白結合型紫杉醇）、放射療法、標靶療法（例如，針對具有特定基因改變的患者的拉羅替尼、恩曲替尼）和免疫療法（例如，針對 MSI-H/dMMR 腫瘤的派姆單抗）。

隨著精準醫療的進步、生物標記驅動療法的日益普及以及政府強力的醫療支持，日本 LAPC 市場正在穩步成長，並為治療創新和患者預後改善帶來重大機會。

市場動態：

駕駛員和約束裝置

採用標靶療法和免疫療法

標靶療法和免疫療法的日益普及代表了日本 LAPC 市場的變革驅動力，重塑了超越傳統化療的治療模式。日本一直處於個人化腫瘤學的前沿，並得到了政府戰略舉措的支持，例如 C-CAT（癌症基因組學和先進治療中心）和 SCRUM-Japan GI-SCREEN，這是全球最大的全國性癌症基因組篩檢計畫之一。這些項目有助於識別胰腺癌患者中可操作的突變和生物標記，從而可以製定超越一刀切治療的客製化治療策略。

日本的醫療保健系統歷來依賴 FOLFIRINOX 和吉西他濱與白蛋白結合型紫杉醇等化療方案，現在正在迅速整合精準醫療，並得到強大的基因組檢測基礎設施和國家醫療保健政策的支持。標靶治療因其能夠干擾特定的癌症遺傳促進因素而得到越來越廣泛的應用，例如用於治療 BRCA 突變腫瘤的 PARP 抑制劑（例如奧拉帕尼）和用於治療 NTRK 融合陽性癌症的 TRK 抑制劑（拉羅替尼、恩曲替尼）。

同樣，獲準用於治療 MSI-H/dMMR 腫瘤的免疫療法（如派姆單抗）也正在獲得廣泛應用，尤其是對於具有明確生物標記的患者而言。伴隨診斷的廣泛應用，加上日本國家保險系統的報銷支持，使得這些療法在各大機構中都能夠得到應用。

日本胰臟學會等機構的臨床指引也開始將這些治療方法納入實踐，加速其採用。總體而言，這種向分子標靶和免疫驅動療法的轉變不僅改善了 LAPC 患者的預後，而且還推動了日本腫瘤市場的創新和成長。

延遲診斷和有限的早期檢測工具

影響日本局部晚期胰腺癌 (LAPC) 市場成長和治療成功的最重大障礙之一是由於缺乏有效的早期檢測工具而導致的診斷延遲。

診斷的延遲不僅限制了手術介入的治療窗口，而且還更依賴化療或放療等全身療法，而這些療法在延長生存期方面通常不如治癒性手術有效。從市場角度來看，這種診斷差距大大減少了適合新興早期介入措施和新療法的潛在患者數量。由於晚期患者需要更密集、更長的治療，這也增加了醫療保健系統的經濟負擔。

因此，缺乏有效的早期檢測工具和隨之而來的延遲診斷對日本 LAPC 領域的臨床結果和市場成長起到了關鍵限制作用。透過改進生物標記研究、人工智慧增強成像診斷或國家篩檢計劃來解決這一差距可能會改變該國胰腺癌管理的格局。

目錄

第1章：市場介紹和範圍

• 報告目標
• 報告範圍和定義
• 報告範圍

第2章：高階主管見解與關鍵要點

• 市場亮點和戰略要點
• 主要趨勢和未來預測
• 療法片段
• 最終用戶的程式碼片段

第3章：動態

• 影響因素
  • 驅動程式
    • 採用標靶療法和免疫療法
    • 老齡化人口中胰臟癌發生率上升
  • 限制
    • 延遲診斷和有限的早期檢測工具
    • 化療的嚴重副作用
  • 機會
    • 精準醫療的進展
  • 影響分析

第4章：戰略洞察與產業展望

• 市場領導者和先驅者
  • 新興先鋒和傑出參與者
  • 擁有最大銷售品牌的既定領導者
  • 擁有成熟產品的市場領導者
• CXO 觀點
• 最新進展與突破
• 案例研究/正在進行的研究
• 監管和報銷情況
• 波特五力分析
• 供應鏈分析
• 專利分析
• SWOT分析
• 未滿足的需求和差距
• 市場進入和擴張的推薦策略
• 情境分析：最佳情況、基本情況和最壞情況預測
• 定價分析和價格動態
• 關鍵意見領袖

第 5 章：日本局部晚期胰臟癌市場（依療法）

• 化療
  • 福菲諾克斯
  • 吉西他濱
  • 白蛋白結合型紫杉醇
  • 順鉑
  • 其他
• 手術
  • Whipple手術
  • 遠端胰臟切除術
  • 全胰臟切除術
• 放射治療
• 標靶治療
  • 拉羅替尼
  • 恩曲替尼
• 免疫療法

第6章：日本局部晚期胰臟癌市場（以最終用戶分類）

• 醫院
• 專科診所
• 研究機構

第7章：競爭格局與市場定位

• 競爭概況和主要市場參與者
• 市佔率分析與定位矩陣
• 策略夥伴關係、併購
• 產品組合和創新的關鍵發展
• 公司基準化分析

第8章：公司簡介

• Bristol-Myers Squibb Company
• 公司概況
• 產品組合
  • 產品描述
  • 產品關鍵績效指標 (KPI)
  • 歷史和預測產品銷售
  • 產品銷售量
• 財務概覽
  • 公司收入
  • 地區收入佔有率
  • 收入預測
• 關鍵進展
  • 併購
  • 關鍵產品開發活動
  • 監管部門批准等
• SWOT分析
• Pfizer Inc.
• Merck & Co., Inc.
• Fresenius Kabi AG
• Teva Pharmaceutical Industries Ltd
• F. Hoffmann-La Roche Ltd.
• Sun Pharmaceutical Industries Ltd.
• Merus NV
• CHEPLAPHARM Arzneimittel GmbH
• Bayer AG
• Eli Lilly and Company
• MITSUBISHI HEAVY INDUSTRIES, LTD.

第9章：假設和研究方法

• 資料收集方法
• 數據三角測量
• 預測技術
• 數據驗證和確認

第 10 章：附錄

The Japan locally advanced pancreatic cancer market reached US$ 47.09 million in 2024 and is expected to reach US$ 89.04 million by 2033, growing at a CAGR of 7.4% during the forecast period 2025-2033.

Locally advanced pancreatic cancer (LAPC) in the market refers to a stage of the disease where the tumor remains confined to the pancreas and surrounding regional structures but has not metastasized to distant organs such as the liver, lungs, or remote lymph nodes. At this stage, the cancer has extended locally and may involve critical nearby structures, including blood vessels like the superior mesenteric artery or portal vein, and organs such as the duodenum, bile ducts, and spleen.

In Japan, LAPC is often classified as unresectable, meaning surgical removal is not feasible due to the tumor's encasement of or proximity to vital blood vessels and nerves. Attempting surgery under these conditions may result in severe complications, which makes non-surgical treatment modalities the primary standard of care.

The current treatment landscape in Japan emphasizes a multimodal approach, combining Chemotherapy (notably FOLFIRINOX or gemcitabine plus nab-paclitaxel), radiation therapy, targeted therapy (e.g., larotrectinib, entrectinib for patients with specific genetic alterations), and immunotherapy (e.g., pembrolizumab for MSI-H/dMMR tumors).

With advancements in precision medicine, growing adoption of biomarker-driven therapies, and strong government healthcare support, the Japanese LAPC market is witnessing steady growth and holds significant opportunities for therapeutic innovation and patient outcome improvement.

Market Dynamics: Drivers & Restraints

Adoption of Targeted and Immunotherapies

The increasing adoption of targeted therapies and immunotherapies represents a transformative driver in the Japan LAPC market, reshaping the treatment paradigm beyond traditional chemotherapy. Japan has been at the forefront of personalized oncology, supported by strategic governmental initiatives such as C-CAT (Center for Cancer Genomics and Advanced Therapeutics) and SCRUM-Japan GI-SCREEN, one of the largest nationwide cancer genomic screening projects globally. These programs facilitate the identification of actionable mutations and biomarkers in pancreatic cancer patients, allowing for tailored therapeutic strategies that go beyond one-size-fits-all treatments.

Historically reliant on chemotherapy regimens like FOLFIRINOX and gemcitabine with nab-paclitaxel, the Japanese healthcare system is now rapidly integrating precision medicine, supported by robust genomic testing infrastructure and national healthcare policies. Targeted therapies, such as PARP inhibitors (e.g., olaparib) for BRCA-mutated tumors and TRK inhibitors (larotrectinib, entrectinib) for NTRK fusion-positive cancers, are being increasingly utilized due to their ability to interfere with specific genetic drivers of cancer.

Similarly, immunotherapies like pembrolizumab, approved for MSI-H/dMMR tumors, are gaining ground, particularly in patients with defined biomarkers. The widespread availability of companion diagnostics, coupled with reimbursement support from Japan's national insurance system, has made these therapies accessible across major institutions.

Clinical guidelines from bodies such as the Japan Pancreas Society have also begun incorporating these treatments into practice, accelerating their adoption. Overall, this shift toward molecularly targeted and immunologically driven therapies is not only improving the prognosis for LAPC patients but is also fueling innovation and growth in Japan's oncology market.

Delayed Diagnosis and Limited Early Detection Tools

One of the most significant barriers impacting the growth and treatment success in the Japan locally advanced pancreatic cancer (LAPC) market is the delayed diagnosis caused by the absence of effective early detection tools.

This delay in diagnosis not only limits the therapeutic window for surgical intervention but also places a heavier reliance on systemic therapies like chemotherapy or radiation, which are often less effective in prolonging survival compared to curative surgery. From a market perspective, this diagnostic gap significantly reduces the potential pool of patients eligible for emerging early-stage interventions and novel therapies. It also increases the economic burden on the healthcare system due to the need for more intensive, prolonged treatments in advanced stages.

Therefore, the lack of effective early detection tools and the consequent delayed diagnosis act as a critical restraint on both clinical outcomes and market growth in Japan's LAPC segment. Addressing this gap through improved biomarker research, AI-enhanced imaging diagnostics, or national screening programs could potentially transform the landscape of pancreatic cancer management in the country.

Segment Analysis

The Japan locally advanced pancreatic cancer market is segmented based on therapy and end-user.

Therapy:

The chemotherapy segment in the therapy is expected to dominate the Japan locally advanced pancreatic cancer market share

Chemotherapy remains the cornerstone of treatment for locally advanced pancreatic cancer (LAPC) in Japan. It works by targeting and killing rapidly dividing cells, including cancerous ones, thereby inhibiting tumor progression. Chemotherapy can be administered as monotherapy or in combination regimens, depending on the patient's performance status and clinical profile.

In Japan, the most commonly used chemotherapy agents for LAPC include Gemcitabine, FOLFIRINOX, Nab-Paclitaxel, Cisplatin, nd Others under clinical evaluation or in combination therapies. The Japan Pancreas Society (JPS) Practice Guidelines 2022 endorse FOLFIRINOX, Gemcitabine + nab-paclitaxel, and Gemcitabine monotherapy as the primary chemotherapy options for managing LAPC.

Japan's structured adherence to evidence-based treatment pathways and its high healthcare infrastructure standard have positioned chemotherapy as a critical pillar in the LAPC market. Its relatively widespread accessibility, strong clinical efficacy, and potential to convert unresectable tumors into operable cases make it a dominant therapeutic strategy.

As ongoing trials investigate newer agents and optimized combinations, chemotherapy is expected to retain its primary role in managing LAPC while evolving in precision and patient personalization.

Competitive Landscape

The major players in the Japan locally advanced pancreatic cancer market include Bristol-Myers Squibb Company, Pfizer Inc., Merck & Co., Inc., Fresenius Kabi AG, Teva Pharmaceutical Industries Ltd, F. Hoffmann-La Roche Ltd., Sun Pharmaceutical Industries Ltd., Merus N.V., CHEPLAPHARM Arzneimittel GmbH, Bayer AG, Eli Lilly and Company, MITSUBISHI HEAVY INDUSTRIES, LTD. and among others.

Key Developments

• In December 2024, Zai Lab Limited and Novocure announced positive results from the Phase 3 PANOVA-3 trial, which achieved its primary endpoint by demonstrating a statistically significant improvement in median overall survival (mOS) compared to the control group. The PANOVA-3 studies evaluated the effectiveness of Tumor Treating Fields (TTFields) therapy used in combination with gemcitabine and nab-paclitaxel as a first-line treatment for patients with unresectable, locally advanced pancreatic adenocarcinoma.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials and product pipelines and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyze product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyze competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Japan locally advanced pancreatic cancer market report delivers a detailed analysis with 42 key tables, more than 25 visually impactful figures, and 136 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Application & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

• 1.1. Objectives of the Report
• 1.2. Report Coverage & Definitions
• 1.3. Report Scope

2. Executive Insights and Key Takeaways

• 2.1. Market Highlights and Strategic Takeaways
• 2.2. Key Trends and Future Projections
• 2.3. Snippet by Therapy
• 2.4. Snippet by End-User

3. Dynamics

• 3.1. Impacting Factors
  • 3.1.1. Drivers
    • 3.1.1.1. Adoption of Targeted and Immunotherapies
    • 3.1.1.2. Rising Incidence of Pancreatic Cancer in an Aging Population
  • 3.1.2. Restraints
    • 3.1.2.1. Delayed Diagnosis and Limited Early Detection Tools
    • 3.1.2.2. Severe Side Effects of Chemotherapy
  • 3.1.3. Opportunity
    • 3.1.3.1. Advancements in Precision Medicine
  • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

• 4.1. Market Leaders and Pioneers
  • 4.1.1. Emerging Pioneers and Prominent Players
  • 4.1.2. Established leaders with the largest-selling Brand
  • 4.1.3. Market leaders with established Product
• 4.2. CXO Perspectives
• 4.3. Latest Developments and Breakthroughs
• 4.4. Case Studies/Ongoing Research
• 4.5. Regulatory and Reimbursement Landscape
• 4.6. Porter's Five Forces Analysis
• 4.7. Supply Chain Analysis
• 4.8. Patent Analysis
• 4.9. SWOT Analysis
• 4.10. Unmet Needs and Gaps
• 4.11. Recommended Strategies for Market Entry and Expansion
• 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
• 4.13. Pricing Analysis and Price Dynamics
• 4.14. Key Opinion Leaders

5. Japan Locally Advanced Pancreatic Cancer Market, By Therapy

• 5.1. Introduction
  • 5.1.1. Analysis and Y-o-Y Growth Analysis (%), By Therapy
  • 5.1.2. Market Attractiveness Index, By Therapy
• 5.2. Chemotherapy*
  • 5.2.1. Introduction
  • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.2.3. Folfirinox
  • 5.2.4. Gemcitabine
  • 5.2.5. Nab-Paclitaxel
  • 5.2.6. Cisplatin
  • 5.2.7. Others
• 5.3. Surgery
  • 5.3.1. Whipple Procedure
  • 5.3.2. Distal Pancreatectomy
  • 5.3.3. Total Pancreatectomy
• 5.4. Radiation Therapy
• 5.5. Targeted Therapy
  • 5.5.1. Larotrectinib
  • 5.5.2. Entrectinib
• 5.6. Immunotherapy

6. Japan Locally Advanced Pancreatic Cancer Market, By End-User

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 6.1.2. Market Attractiveness Index, By End-User
• 6.2. Hospitals*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Specialty Clinics
• 6.4. Research Institutions

7. Competitive Landscape and Market Positioning

• 7.1. Competitive Overview and Key Market Players
• 7.2. Market Share Analysis and Positioning Matrix
• 7.3. Strategic Partnerships, Mergers & Acquisitions
• 7.4. Key Developments in Product Portfolios and Innovations
• 7.5. Company Benchmarking

8. Company Profiles

• 8.1. Bristol-Myers Squibb Company
  • 8.1.1. Company Overview
  • 8.1.2. Product Portfolio
    • 8.1.2.1. Product Description
    • 8.1.2.2. Product Key Performance Indicators (KPIs)
    • 8.1.2.3. Historic and Forecasted Product Sales
    • 8.1.2.4. Product Sales Volume
  • 8.1.3. Financial Overview
    • 8.1.3.1. Company Revenue's
    • 8.1.3.2. Geographical Revenue Shares
    • 8.1.3.3. Revenue Forecasts
  • 8.1.4. Key Developments
    • 8.1.4.1. Mergers & Acquisitions
    • 8.1.4.2. Key Product Development Activities
    • 8.1.4.3. Regulatory Approvals, etc.
  • 8.1.5. SWOT Analysis
• 8.2. Pfizer Inc.
• 8.3. Merck & Co., Inc.
• 8.4. Fresenius Kabi AG
• 8.5. Teva Pharmaceutical Industries Ltd
• 8.6. F. Hoffmann-La Roche Ltd.*
• 8.7. Sun Pharmaceutical Industries Ltd.
• 8.8. Merus N.V.
• 8.9. CHEPLAPHARM Arzneimittel GmbH
• 8.10. Bayer AG
• 8.11. Eli Lilly and Company
• 8.12. MITSUBISHI HEAVY INDUSTRIES, LTD.

LIST NOT EXHAUSTIVE

9. Assumptions and Research Methodology

• 9.1. Data Collection Methods
• 9.2. Data Triangulation
• 9.3. Forecasting Techniques
• 9.4. Data Verification and Validation

10. Appendix

• 10.1. About Us and Services
• 10.2. Contact Us